Ishida H, Tanabe K, Furusawa M, Isizuka T, Tokumoto T, Shimmura H, Shimizu T, Miyamoto N, Hayashi T, Toma H
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Transplant Proc. 2004 Sep;36(7):2178-81. doi: 10.1016/j.transproceed.2004.08.082.
We used an enzyme linked immunosorbent assay (ELISA) to investigate the presence of subtypes of anti-blood-type antibodies in patients with biopsy-proven humoral rejection after ABO-incompatible renal transplantation. High agglutinin IgG and IgM anti-blood type antibodies from 12 ABO-incompatible recipients with vascular rejection were separately assessed using an ELISA. Patients who exhibited excellent renal function despite high agglutinin titers of anti-blood-type antibodies(n = 8) were also examined. All 12 rejection patients exhibited highly elevated titers of IgG and IgM, while the eight stable patients exhibited only slightly elevated IgG titers, but not IgM. IgG and IgM titers did not change after plasmapheresis and steroid pulse therapy, whereas IVIg treatment significantly blocked both IgG and IgM, with IgM being blocked to a larger extent than IgG. Blocking of IgM seems to play an important role in improving ABO-incompatible grafts.
我们采用酶联免疫吸附测定(ELISA)法,对经活检证实发生体液排斥反应的ABO血型不相容肾移植患者体内抗血型抗体亚型的存在情况进行了研究。使用ELISA法分别评估了12例发生血管排斥反应的ABO血型不相容受者体内的高凝集素IgG和IgM抗血型抗体。对于尽管抗血型抗体凝集素滴度很高但肾功能良好的患者(n = 8)也进行了检查。所有12例发生排斥反应的患者IgG和IgM滴度均显著升高,而8例病情稳定的患者仅IgG滴度略有升高,IgM未升高。血浆置换和类固醇冲击治疗后,IgG和IgM滴度未发生变化,而静脉注射免疫球蛋白(IVIg)治疗显著阻断了IgG和IgM,其中IgM的阻断程度大于IgG。阻断IgM似乎在改善ABO血型不相容移植物方面发挥着重要作用。